Search

Your search keyword '"Haddad, P."' showing total 68 results
Start Over Author "Haddad, P." Journal journal of clinical oncology
68 results on '"Haddad, P."'

1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

Author

Steger, Guenther, Hernando Fernández de Aránguiz, Blanca, Haddad, Tufia, Perelló, Antonia, Bellet, Meritxell, Fohler, Hannes, Metzger Filho, Otto, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline, Theall, Kathy, Lu, Dongrui, Tenner, Kathleen, Fesl, Christian, DeMichele, Angela, Mayer, Erica, Gnant, Michael, Dueck, Amylou, Frantal, Sophie, Martin, Miguel, Burstein, Hal, Greil, Richard, Fox, Peter, Wolff, Antonio, Chan, Arlene, Winer, Eric, Pfeiler, Georg, Miller, Kathy, Colleoni, Marco, Suga, Jennifer, Rubovsky, Gabor, Bliss, Judith, Mayer, Ingrid, Singer, Christian, Nowecki, Zbigniew, Hahn, Olwen, Thomson, Jacqui, Wolmark, Norman, Amillano, Kepa, and Rugo, Hope

Subjects
Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Female, Humans, Mastectomy, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Piperazines, Progression-Free Survival, Prospective Studies, Protein Kinase Inhibitors, Pyridines, Time Factors
Abstract

PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer-free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer.

Published
2022

2. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer

Author

Spratt, Daniel E, Zhang, Jingbin, Santiago-Jiménez, María, Dess, Robert T, Davis, John W, Den, Robert B, Dicker, Adam P, Kane, Christopher J, Pollack, Alan, Stoyanova, Radka, Abdollah, Firas, Ross, Ashley E, Cole, Adam, Uchio, Edward, Randall, Josh M, Nguyen, Hao, Zhao, Shuang G, Mehra, Rohit, Glass, Andrew G, Lam, Lucia LC, Chelliserry, Jijumon, du Plessis, Marguerite, Choeurng, Voleak, Aranes, Maria, Kolisnik, Tyler, Margrave, Jennifer, Alter, Jason, Jordan, Jennifer, Buerki, Christine, Yousefi, Kasra, Haddad, Zaid, Davicioni, Elai, Trabulsi, Edouard J, Loeb, Stacy, Tewari, Ashutosh, Carroll, Peter R, Weinmann, Sheila, Schaeffer, Edward M, Klein, Eric A, Karnes, R Jeffrey, Feng, Felix Y, and Nguyen, Paul L

Subjects
Urologic Diseases, Prevention, Clinical Research, Cancer, Prostate Cancer, Genetics, Human Genome, Aging, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Aged, Genomics, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms, Risk, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorable-intermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the three-tier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95% CI, 0.65 to 0.84), and 30% of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low- to very-high-risk) by the new six-tier system. Conclusion A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk for metastasis and can be easily incorporated into current guidelines to better risk-stratify patients.

Published
2018

3. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease

Author

Spratt, Daniel E, Yousefi, Kasra, Deheshi, Samineh, Ross, Ashley E, Den, Robert B, Schaeffer, Edward M, Trock, Bruce J, Zhang, Jingbin, Glass, Andrew G, Dicker, Adam P, Abdollah, Firas, Zhao, Shuang G, Lam, Lucia LC, du Plessis, Marguerite, Choeurng, Voleak, Haddad, Zaid, Buerki, Christine, Davicioni, Elai, Weinmann, Sheila, Freedland, Stephen J, Klein, Eric A, Karnes, R Jeffrey, and Feng, Felix Y

Subjects
Aging, Cancer, Prevention, Aged, Biomarkers, Tumor, Follow-Up Studies, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Metastasis, Nomograms, Prognosis, Prostatectomy, Prostatic Neoplasms, Risk Assessment, Risk Factors, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose To perform the first meta-analysis of the performance of the genomic classifier test, Decipher, in men with prostate cancer postprostatectomy. Methods MEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher test. Multivariable Cox proportional hazards models fit to individual patient data were performed; meta-analyses were conducted by pooling the study-specific hazard ratios (HRs) using random-effects modeling. Extent of heterogeneity between studies was determined with the I2 test. Results Five studies (975 total patients, and 855 patients with individual patient-level data) were eligible for analysis, with a median follow-up of 8 years. Of the total cohort, 60.9%, 22.6%, and 16.5% of patients were classified by Decipher as low, intermediate, and high risk, respectively. The 10-year cumulative incidence metastases rates were 5.5%, 15.0%, and 26.7% ( P < .001), respectively, for the three risk classifications. Pooling the study-specific Decipher HRs across the five studies resulted in an HR of 1.52 (95% CI, 1.39 to 1.67; I2 = 0%) per 0.1 unit. In multivariable analysis of individual patient data, adjusting for clinicopathologic variables, Decipher remained a statistically significant predictor of metastasis (HR, 1.30; 95% CI, 1.14 to 1.47; P < .001) per 0.1 unit. The C-index for 10-year distant metastasis of the clinical model alone was 0.76; this increased to 0.81 with inclusion of Decipher. Conclusion The genomic classifier test, Decipher, can independently improve prognostication of patients postprostatectomy, as well as within nearly all clinicopathologic, demographic, and treatment subgroups. Future study of how to best incorporate genomic testing in clinical decision-making and subsequent treatment recommendations is warranted.

Published
2017

4. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Author

Bauml, Joshua, Seiwert, Tanguy Y, Pfister, David G, Worden, Francis, Liu, Stephen V, Gilbert, Jill, Saba, Nabil F, Weiss, Jared, Wirth, Lori, Sukari, Ammar, Kang, Hyunseok, Gibson, Michael K, Massarelli, Erminia, Powell, Steven, Meister, Amy, Shu, Xinxin, Cheng, Jonathan D, and Haddad, Robert

Subjects
Clinical Research, Rare Diseases, Sexually Transmitted Infections, Dental/Oral and Craniofacial Disease, Cancer, Infectious Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, B7-H1 Antigen, Carcinoma, Squamous Cell, Cetuximab, Disease Progression, Disease-Free Survival, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Papillomavirus Infections, Platinum Compounds, Response Evaluation Criteria in Solid Tumors, Retreatment, Survival Rate, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-055 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor prognosis. Methods Eligibility stipulated disease progression within 6 months of platinum and cetuximab treatment. Patients received pembrolizumab 200 mg every 3 weeks. Imaging was performed every 6 to 9 weeks. Primary end points: overall response rate (Response Evaluation Criteria in Solid Tumors v1.1, central review) and safety. Efficacy was assessed in all dosed patients and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status. Results Among 171 patients treated, 75% received two or more prior lines of therapy for metastatic disease, 82% were PD-L1 positive, and 22% were HPV positive. At the time of analysis, 109 patients (64%) experienced a treatment-related adverse event; 26 patients (15%) experienced a grade ≥ 3 event. Seven patients (4%) discontinued treatment, and one died of treatment-related adverse events. Overall response rate was 16% (95% CI, 11% to 23%), with a median duration of response of 8 months (range, 2+ to 12+ months); 75% of responses were ongoing at the time of analysis. Response rates were similar in all HPV and PD-L1 subgroups. Median progression-free survival was 2.1 months, and median overall survival was 8 months. Conclusion Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab.

Published
2017

5. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Author

Chow, Laura QM, Haddad, Robert, Gupta, Shilpa, Mahipal, Amit, Mehra, Ranee, Tahara, Makoto, Berger, Raanan, Eder, Joseph Paul, Burtness, Barbara, Lee, Se-Hoon, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Weiss, Jared, Geva, Ravit, Lin, Chia-Chi, Chung, Hyun Cheol, Meister, Amy, Dolled-Filhart, Marisa, Pathiraja, Kumudu, Cheng, Jonathan D, and Seiwert, Tanguy Y

Subjects
Clinical Research, Cancer, Dental/Oral and Craniofacial Disease, Rare Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, B7-H1 Antigen, Carcinoma, Squamous Cell, Cohort Studies, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported. Patients and Methods Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pembrolizumab 200 mg intravenously once every 3 weeks. Imaging was performed every 8 weeks. Primary end points were overall response rate (ORR) per central imaging vendor (Response Evaluation Criteria in Solid Tumors v1.1) and safety. Secondary end points included progression-free survival, overall survival, and association of response and PD-L1 expression. Patients who received one or more doses of pembrolizumab were included in analyses. Results Of 132 patients enrolled, median age was 60 years (range, 25 to 84 years), 83% were male, and 57% received two or more lines of therapy for R/M disease. ORR was 18% (95% CI, 12 to 26) by central imaging vendor and 20% (95% CI, 13 to 28) by investigator review. Median duration of response was not reached (range, ≥ 2 to ≥ 11 months). Six-month progression-free survival and overall survival rates were 23% and 59%, respectively. By using tumor and immune cells, a statistically significant increase in ORR was observed for PD-L1-positive versus -negative patients (22% v 4%; P = .021). Treatment-related adverse events of any grade and grade ≥ 3 events occurred in 62% and 9% of patients, respectively. Conclusion Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.

Published
2016

8. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.

Author

Haddad, Robert I., Harrington, Kevin, Tahara, Makoto, Ferris, Robert L., Gillison, Maura, Fayette, Jerome, Daste, Amaury, Koralewski, Piotr, Zurawski, Bogdan, Taberna, Miren, Saba, Nabil F., Mak, Milena, Kawecki, Andrzej, Girotto, Gustavo, Alvarez Avitia, Miguel Angel, Even, Caroline, Toledo, Joaquin Gabriel Reinoso, Guminski, Alexander, Müller-Richter, Urs, and Kiyota, Naomi

Published
2023
Full Text
View/download PDF

9. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.

Author

Singh, Navneet, Temin, Sarah, Baker Jr, Sherman, Blanchard, Elizabeth, Brahmer, Julie R., Celano, Paul, Duma, Narjust, Ellis, Peter M., Elkins, Ivy B., Haddad, Rami Y., Hesketh, Paul J., Jain, Dharamvir, Johnson, David H., Leighl, Natasha B., Mamdani, Hirva, Masters, Gregory, Moffitt, Pamela R., Phillips, Tanyanika, Riely, Gregory J., and Robinson, Andrew G.

Published
2022
Full Text
View/download PDF

10. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer...

Author

Mayer, Erica L, Fesl, Christian, Hlauschek, Dominik, Garcia-Estevez, Laura, Burstein, Harold J, Zdenkowski, Nicholas, Wette, Viktor, Miller, Kathy D, Balic, Marija, Mayer, Ingrid A, Cameron, David, Winer, Eric P, Ponce Lorenzo, José Juan, Lake, Diana, Pristauz-Telsnigg, Gunda, Haddad, Tufia C, Shepherd, Lois, Iwata, Hiroji, Goetz, Matthew, and Cardoso, Fatima

Published
2022
Full Text
View/download PDF

11. Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations.

Author

Ho, Alan L, Brana, Irene, Haddad, Robert, Bauman, Jessica, Bible, Keith, Oosting, Sjoukje, Wong, Deborah J, Ahn, Myung-Ju, Boni, Valentina, Even, Caroline, Fayette, Jerome, Flor, Maria José, Harrington, Kevin, Kim, Sung-Bae, Licitra, Lisa, Nixon, Ioanna, Saba, Nabil F, Hackenberg, Stephan, Specenier, Pol, and Worden, Francis

Published
2021
Full Text
View/download PDF

12. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

Author

Hanna, Nasser H, Robinson, Andrew G, Temin, Sarah, Baker, Sherman Jr, Brahmer, Julie R, Ellis, Peter M, Gaspar, Laurie E, Haddad, Rami Y, Hesketh, Paul J, Jain, Dharamvir, Jaiyesimi, Ishmael, Johnson, David H, Leighl, Natasha B, Moffitt, Pamela R, Phillips, Tanyanika, Riely, Gregory J, Rosell, Rafael, Schiller, Joan H, Schneider, Bryan J, and Singh, Navneet

Published
2021
Full Text
View/download PDF

13. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.

Author

Chen, Yu-Pei, Ismaila, Nofisat, Chua, Melvin L K, Colevas, A Dimitrios, Haddad, Robert, Huang, Shao Hui, Wee, Joseph T S, Whitley, Alexander C, Yi, Jun-Lin, Yom, Sue S, Chan, Anthony T C, Hu, Chao-Su, Lang, Jin-Yi, Le, Quynh-Thu, Lee, Anne W M, Lee, Nancy, Lin, Jin-Ching, Ma, Brigette, Morgan, Thomas J, and Shah, Jatin

Published
2021
Full Text
View/download PDF

15. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

Author

Hanna, Nasser H., Schneider, Bryan J., Temin, Sarah, Baker, Sherman, Brahmer, Julie, Ellis, Peter M., Gaspar, Laurie E., Haddad, Rami Y., Hesketh, Paul J., Jain, Dharamvir, Jaiyesimi, Ishmael, Johnson, David H., Leighl, Natasha B., Phillips, Tanyanika, Riely, Gregory J., Robinson, Andrew G., Rosell, Rafael, Schiller, Joan H., Singh, Navneet, and Spigel, David R.

Published
2020
Full Text
View/download PDF

16. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

Author

Yadav, Siddhartha, Hu, Chunling, Hart, Steven N., Boddicker, Nicholas, Polley, Eric C., Na, Jie, Gnanaolivu, Rohan, Lee, Kun Y., Lindstrom, Tricia, Armasu, Sebastian, Fitz-Gibbon, Patrick, Ghosh, Karthik, Stan, Daniela L., Pruthi, Sandhya, Neal, Lonzetta, Sandhu, Nicole, Rhodes, Deborah J., Klassen, Christine, Peethambaram, Prema P., and Haddad, Tufia C.

Published
2020
Full Text
View/download PDF

17. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Author

Mok, Tony S. K., Kim, Sang-We, Yi-Long Wu, Kazuhiko Nakagawa, Jin-Ji Yang, Ahn, Myung-Ju, Jie Wang, Yang, James Chih-Hsin, Lu, You, Shinji Atagi, Ponce, Santiago, Xiaojin Shi, Rukazenkov, Yuri, Haddad, Vincent, Thress, Kenneth S., Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Yang, Jin-Ji, and Wang, Jie

Published
2017
Full Text
View/download PDF

22. Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.

Author

Zoghbi, Marianne, Jabbour, Elias, Haddad, Fadi, Short, Nicholas James, Senapati, Jayastu, Macaron, Walid, Nasnas, Cedric Christophe, Nasr, Lewis Fady, Pemmaraju, Naveen, Jain, Nitin, Wierda, William G., Borthakur, Gautam, Bravo, Guillermo Montalban, Ravandi, Farhad, Garcia-Manero, Guillermo, Kadia, Tapan M., Chien, Kelly Sharon, Thankachan, Jennifer, Garris, Rebecca, and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

23. Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase.

Author

Zoghbi, Marianne, Jabbour, Elias, Haddad, Fadi, Short, Nicholas James, Nasnas, Cedric Christophe, Macaron, Walid, Nasr, Lewis Fady, Jain, Nitin, Montalban-Bravo, Guillermo, Kadia, Tapan M., Daver, Naval Guastad, Chien, Kelly Sharon, Alvarado Valero, Yesid, Issa, Ghayas C., Mayor, Ejiroghene, Deen, Wuliamatu, Thankachan, Jennifer, Garris, Rebecca, Ravandi, Farhad, and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

24. Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Author

Nasnas, Cedric Christophe, Jabbour, Elias, Haddad, Fadi, Short, Nicholas James, Macaron, Walid, Zoghbi, Marianne, Nasr, Lewis Fady, Jain, Nitin, Almanza, Emmanuel, Sasaki, Koji, Ravandi, Farhad, Kebriaei, Partow, Huang, Xuelin, Garcia-Manero, Guillermo, Kadia, Tapan M., Wang, Sa A, Jacob, Jovitta, Garris, Rebecca, O'Brien, Susan M., and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

25. Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.

Author

Nasr, Lewis Fady, Jabbour, Elias, Haddad, Fadi, Short, Nicholas James, Macaron, Walid, Nasnas, Cedric Christophe, Zoghbi, Marianne, Issa, Ghayas C., Yilmaz, Musa, Daver, Naval Guastad, Pemmaraju, Naveen, Masarova, Lucia, Ravandi, Farhad, Jain, Nitin, Deen, Wuliamatu, Loiselle, Christopher, Waller, Lourdes, Banks, Glenda, Garris, Rebecca, and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

26. Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial.

Author

Nasnas, Cedric Christophe, Jabbour, Elias, Haddad, Fadi, Short, Nicholas James, Nasr, Lewis Fady, Macaron, Walid, Zoghbi, Marianne, Ravandi, Farhad, Jain, Nitin, Kadia, Tapan M., Daver, Naval Guastad, Borthakur, Gautam, Dinardo, Courtney Denton, Jacob, Jovitta, Roy, Edith, Loiselle, Christopher, Milton, Anna, Rivera, Juan, Garris, Rebecca, and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

27. A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

Author

Short, Nicholas James, Jabbour, Elias, Jain, Nitin, Haddad, Fadi, Macaron, Walid, Yilmaz, Musa, Ferrajoli, Alessandra, Kadia, Tapan M., Alvarado Valero, Yesid, Maiti, Abhishek, Nasr, Lewis Fady, Zoghbi, Marianne, Nasnas, Cedric Christophe, Garris, Rebecca, Zhao, Min, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

28. A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Author

Short, Nicholas James, Jabbour, Elias, Jain, Nitin, Macaron, Walid, Huang, Xuelin, Montalban-Bravo, Guillermo, Kadia, Tapan M., Daver, Naval Guastad, Haddad, Fadi, Zoghbi, Marianne, Nasnas, Cedric Christophe, Nasr, Lewis Fady, Mayor, Ejiroghene, Deen, Wuliamatu, Thankachan, Jennifer, Loiselle, Christopher, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop M.

Published
2023
Full Text
View/download PDF

37. Building a predictive model for outcomes with [ 177 Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.

Author

Herrmann, Ken, Gafita, Andrei, De Bono, Johann S., Sartor, A. Oliver, Chi, Kim N., Krause, Bernd J., Rahbar, Kambiz, Tagawa, Scott T., Czernin, Johannes, El-Haddad, Ghassan, Wong, Connie, Zhang, Zhaojie, Wilke, Celine, Mirante, Osvaldo, Morris, Michael J., and Fizazi, Karim

Published
2023
Full Text
View/download PDF

38. A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Author

Saltos, Andreas Nicholas, Arrowood, Christy, Beasley, Georgia, Ronald, James, El-Haddad, Ghassan, Guerra-Guevara, Luiziane, Khan, Uzma, Wolf, Steven, Gu, Lin, Wang, Xiaofei F., Foresman, Dana, Yu, Xiaoqing, Cantwell, Mark J., Antonia, Scott Joseph, Beg, Amer A, and Ready, Neal E.

Published
2023
Full Text
View/download PDF

39. Decreasing the burden of febrile neutropenia through dynamic remote patient monitoring: The DEFeNDER program.

Author

Pritchett, Joshua, Paludo, Jonas, Shi, Qian, Khera, Nandita, Yetmar, Zachary, Wilson, John W., McCoy, Rozalina, Leuenberger, Angela, Phillips, Sarah, Pearson, Kristina, McColley, Samantha, Haemmerle, Robert, Sangaralingham, Lindsey R., Ryu, Alexander J., Phelan, David, Gangat, Naseema, Molina, Julian R., Tilburt, Jon Charles, Borah, Bijan J., and Haddad, Tufia C.

Published
2023
Full Text
View/download PDF

40. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

Author

Goetz, Matthew P., Suman, Vera J., Reid, Joel M., Northfelt, Don W., Mahr, Michael A., Ralya, Andrew T., Kuffel, Mary, Buhrow, Sarah A., Safgren, Stephanie L., McGovern, Renee M., Black, John, Dockter, Travis, Haddad, Tufia, Erlichman, Charles, Adjei, Alex A., Visscher, Dan, Chalmers, Zachary R., Frampton, Garrett, Kipp, Benjamin R., and Liu, Minetta C.

Published
2017
Full Text
View/download PDF

41. Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

Author

Gudenkauf, Lisa M., Chavez, Melody, Maconi, Melinda, Geiss, Carley, Seyedroudbari, Ameen, Thin, Pan, Hoogland, Aasha, Nguyen, Kathleen, Oswald, Laura B., Jim, Heather S.L., El-Haddad, Ghassan, Fendler, Wolfgang Peter, Herrmann, Ken, Cella, David, Czernin, Johannes, Hofman, Michael S, Dicker, Adam P., Calais, Jeremie, Tagawa, Scott T., and Gonzalez, Brian D.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results